SAN FRANCISCO, October 22, 2024 - Osso VR, the leading provider of immersive healthcare experiences, announced its strategic expansion into custom extended reality (XR) healthcare solutions tailored specifically for pharmaceutical companies’ breakthrough products and treatments.
The pharmaceutical industry is undergoing significant growth, with the implantable drug delivery market projected to rise from $24.67 billion in 2021 to $45.67 billion by 2029. To help companies navigate key commercial and clinical challenges, Osso VR utilizes advanced XR technology and its award-winning platform to deliver experiences that span the product lifecycle—from clinical trials to launch—ensuring teams are well-trained, confident, and ready to perform successfully.
Osso VR’s XR experiences serve as a powerful differentiator for sales and marketing leaders’ commercial strategies. With just a headset, teams gain real-time, on-demand access to complex therapeutics and procedures, offering a compelling way to engage healthcare professionals (HCPs) in a virtual environment while dismantling traditional barriers to entry. The experiences also address logistical challenges often associated with conferences and clinical trials, delivering a novel way to interact with products and boosting participation. Finally, the content acts as a valuable patient engagement tool, fostering deeper understanding and empathy through high-fidelity, realistic training.
Within each immersive experience, users virtually interact with content to enhance their knowledge, explore unique scenarios, raise disease state awareness, and bring mechanisms of action to life. Each experience includes access to the Osso VR platform, which features powerful analytics that provide personalized dashboards for objective assessment and global reporting for leaders to see key insights into XR program effectiveness. The platform will also feature distinct tools that enable companies to visually narrate their product stories, including a robust patient library for matching demographics to medications and resources for visualizing symptom clusters and treatment effects.
“As pharmaceutical companies face the growing challenge of access to clinicians and educating patient populations, particularly as therapeutics become more complex, Osso VR offers a powerful, differentiated solution that can reshape commercial and clinical strategies,” said Heather Gervais, CEO of Osso VR. “By addressing these shifting demands, we’re not just enabling better communication among stakeholders; we’re also committed to improving the healthcare experience for everyone involved, including better outcomes for patients.”
For more information about Osso VR, visit https://www.ossovr.com.
Used by the world’s leading healthcare companies and hospital systems, Osso VR creates award-winning, clinically validated XR training experiences. Osso’s flagship solution, Osso Enterprise, develops customized, immersive medical content that provides a collaborative, risk-free, hands-on training environment and incorporates a proprietary analytics platform to measure performance and outcome improvement.
Co-founded in 2016 by UCLA and Harvard-trained pediatric orthopedic surgeon Justin Barad, MD, Osso VR has been the most celebrated XR company in healthcare, earning multiple industry awards, including TIME Magazine’s Best Inventions, Fast Company’s Most Innovative Healthcare Company, and the SXSW Innovation Award for VR. Osso VR develops content for numerous healthcare industries and is available in several languages in over 40 countries.
To learn more, visit www.ossovr.com, and follow Osso VR on LinkedIn, Twitter and Instagram.
Media Contact:
AM Public Relations
osso@ampublicrelations.com
